Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
Cingulate Chairman and CEO Shane Schaffer and Chief Commercial Officer Bryan Downey will participate in two sessions at the Indegene Digital Summit on September 22, 2026, at the National Constitution Center in Philadelphia. Schaffer joins 'The SMART Launch' panel on how emerging pharma companies can retain ownership and strategic control of their assets while accessing external partner capabilities, positioning it as a more capital-efficient alternative to building large internal commercial infrastructure or licensing assets to larger drugmakers.
Key figures
- Fda crl date
- June 1, 2026
- Patients under 17
- over 8 million
- Adult adhd patients
- 12 million
- Pdufa target action date
- May 31, 2026
- Us diagnosed adhd patients
- over 20 million
- Us adhd annual prescriptions
- approximately 100 million
- Symptom persistence into adulthood
- 65-90 percent
- Pediatric medication treatment rate 2022
- 53.6 percent
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.